{"id":8738,"date":"2026-09-11T08:50:43","date_gmt":"2026-09-11T05:50:43","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8738"},"modified":"2026-09-11T08:50:46","modified_gmt":"2026-09-11T05:50:46","slug":"exegenesis-modalis-mdl-201-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/exegenesis-modalis-mdl-201-dmd\/","title":{"rendered":"Exegenesis Bio ve Modalis, Duchenne Kas Distrofisi i\u00e7in MDL-201&#039;i Geli\u015ftirmek \u00dczere \u0130\u015f Birli\u011fi Yap\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Exegenesis Bio ve Modalis Therapeutics Corporation, Duchenne kas distrofisi (DMD) i\u00e7in potansiyel yeni bir tedavi olan MDL-201&#039;i geli\u015ftirmek amac\u0131yla bir ara\u015ft\u0131rma i\u015f birli\u011fi ve lisans anla\u015fmas\u0131 duyurdu.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu i\u015f birli\u011fi iki teknolojiyi bir araya getiriyor: Modalis'in CRISPR-GNDM epigenom d\u00fczenleme platformu ve Exegenesis Bio'nun EMC181 kas hedefli AAV kapsidi. Anla\u015fman\u0131n 14 Eyl\u00fcl 2026'da y\u00fcr\u00fcrl\u00fc\u011fe girmesi bekleniyor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Duchenne Tedavisine Farkl\u0131 Bir Yakla\u015f\u0131m<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MDL-201, mutasyondan ba\u011f\u0131ms\u0131z bir tedavi olarak geli\u015ftirilmektedir; yani, belirli mutasyonlarla s\u0131n\u0131rl\u0131 kalmak yerine, DMD&#039;li geni\u015f bir hasta yelpazesini potansiyel olarak hedef almas\u0131 ama\u00e7lanmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MDL-201, distrofin genini de\u011fi\u015ftirmeye \u00e7al\u0131\u015fmak yerine, kaslarda distrofinin i\u015flevini k\u0131smen tamamlayabilecek bir protein olan \u00fctrofinin \u00fcretimini art\u0131rmak \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu terapi, Modalis'in tescilli CRISPR-GNDM (K\u0131lavuz N\u00fckleotid Y\u00f6nlendirmeli Mod\u00fclasyon) teknolojisini kullanmaktad\u0131r. DNA'y\u0131 kesebilen geleneksel CRISPR yakla\u015f\u0131mlar\u0131n\u0131n aksine, CRISPR-GNDM, DNA'n\u0131n her iki ipli\u011fini de kesmeden gen ekspresyonunu d\u00fczenlemek \u00fczere tasarlanm\u0131\u015ft\u0131r. MDL-201 i\u00e7in ama\u00e7, kas dokusunda utrofin genini se\u00e7ici ve s\u00fcrd\u00fcr\u00fclebilir bir \u015fekilde aktive etmektir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">AAV Kapsidinin \u00d6nemi<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu i\u015fbirli\u011finin kilit noktalar\u0131ndan biri de Exegenesis Bio'nun EMC181 AAV kapsididir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AAV kapsidleri, gen terapisiyle ilgili y\u00fcklerin hedef h\u00fccrelere ta\u015f\u0131nmas\u0131na yard\u0131mc\u0131 olmak i\u00e7in kullan\u0131lan ta\u015f\u0131y\u0131c\u0131 bile\u015fenlerdir. EMC181, kas dokusuna y\u00fcksek tropizme sahip olacak \u015fekilde tasarlanm\u0131\u015f olup ayn\u0131 zamanda karaci\u011ferden uzakla\u015ft\u0131rma \u00f6zelliklerine de sahiptir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu kombinasyonun amac\u0131, kaslara ila\u00e7 iletimini art\u0131r\u0131rken karaci\u011fer gibi organlara maruz kalmay\u0131 azaltmakt\u0131r. \u015eirketler, bunun MDL-201&#039;in terap\u00f6tik profilini potansiyel olarak iyile\u015ftirebilece\u011fine inan\u0131yor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u0130ki Teknolojinin Birle\u015ftirilmesi<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu i\u015f birli\u011fi, Exegenesis Bio'nun gen terapisi uygulama teknolojisini, Modalis'nin CRISPR-GNDM y\u00fck\u00fc ve geli\u015ftirme deneyimiyle birle\u015ftiriyor.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Exegenesis Bio, EMC181&#039;e katk\u0131da bulunacakken, Modalis ise MDL-201 i\u00e7in CRISPR-GNDM teknolojisine sahip kapsidi kullanacak. \u015eirketler, kas hedefli ila\u00e7 da\u011f\u0131t\u0131m\u0131n\u0131 iyile\u015ftirmeyi ve program\u0131 klinik \u00f6ncesi ve nihayetinde klinik geli\u015ftirme a\u015famalar\u0131na ta\u015f\u0131may\u0131 hedefliyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Modalis CEO&#039;su Haruhiko Morita, bu kombinasyonun, uzun vadeli hedefi farkl\u0131 DMD mutasyonlar\u0131nda uygulanabilecek farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f bir tedavi yakla\u015f\u0131m\u0131 geli\u015ftirmek olan, kal\u0131c\u0131 \u00fctrofin aktivasyonu ve kas hedefli ila\u00e7 da\u011f\u0131t\u0131m\u0131n\u0131 bir araya getirdi\u011fini belirtti.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Bu, DMD toplulu\u011fu i\u00e7in ne anlama geliyor?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MDL-201, distrofinin do\u011frudan yerine konmas\u0131n\u0131 veya eski haline getirilmesini ama\u00e7layan tedavilerden farkl\u0131 bir yakla\u015f\u0131m\u0131 temsil etmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak, MDL-201&#039;in hala ara\u015ft\u0131rma ve geli\u015ftirme a\u015famas\u0131nda oldu\u011funu anlamak \u00f6nemlidir. Duyuruda, program\u0131n klinik \u00f6ncesi ve klinik geli\u015ftirmeye do\u011fru ilerletilmesine y\u00f6nelik planlar a\u00e7\u0131klanmaktad\u0131r; hastalarda klinik etkinlik veya g\u00fcvenlik sonu\u00e7lar\u0131 bildirilmemektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirketlerin \u00f6ncelikli hedefi, teknolojilerini birle\u015ftirerek MDL-201&#039;in geli\u015ftirilmesini h\u0131zland\u0131rmakt\u0131r. Program ba\u015far\u0131l\u0131 bir \u015fekilde ilerlerse, Duchenne kas distrofisi i\u00e7in potansiyel bir tedavi stratejisi daha olu\u015fturabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha Fazlas\u0131n\u0131 Ke\u015ffedin<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/map\/\" target=\"_blank\" rel=\"noopener\">Duchenne Klinik Ara\u015ft\u0131rma Yerleri Haritas\u0131<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Exegenesis Bio and Modalis Therapeutics Corporation have announced a research collaboration and license agreement to advance MDL-201, a potential new treatment for Duchenne muscular dystrophy (DMD). The collaboration brings together two technologies: Modalis\u2019 CRISPR-GNDM epigenome editing platform and Exegenesis Bio\u2019s EMC181 muscle-targeting AAV capsid. The agreement is expected to become effective on September 14, 2026. [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":8741,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[907,906,909,908],"class_list":["post-8738","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-crispr-gndm","tag-exegenesis-bio","tag-mdl-201","tag-modalis-therapeutics"],"subtitle":"Exegenesis Bio ve Modalis, Duchenne kas distrofisi i\u00e7in potansiyel yeni bir yakla\u015f\u0131m olan MDL-201'i geli\u015ftirmek \u00fczere g\u00fc\u00e7lerini birle\u015ftiriyor. Bu tedavi, CRISPR-GNDM ve hedeflenmi\u015f AAV da\u011f\u0131t\u0131m\u0131 kullanarak utrofini aktive etmeyi ama\u00e7l\u0131yor.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8738"}],"version-history":[{"count":2,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8738\/revisions"}],"predecessor-version":[{"id":8740,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8738\/revisions\/8740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8741"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}